Xbrane Biopharma AB News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

06.02.18	Xbrane Biopharma signs license agreement with CR Pharma for Spherotide in China (GlobeNewswire)
22.12.17	Serendipity Ixora proposes distribution of its Xbrane shares to its shareholders, after which Serendipity Group becomes the largest shareholder in Xbrane if the distribution is executed (GlobeNewswire)
22.12.17	Xbrane Biopharma largest shareholder Serendipity Group issues a credit facility of SEK 50 million to the company (GlobeNewswire)
21.12.17	Xbrane Biopharma informs about ongoing negotiations concerning out-licensing of Spherotide to China (GlobeNewswire)
19.12.17	Xbrane Biopharma signs agreement with BL&H for sales and marketing of Spherotide in South Korea (GlobeNewswire)
13.12.17	Xbrane Biopharma informs about changes in management team (GlobeNewswire)
13.11.17	Xbrane Biopharma releases interim report for the period July to September 2017 (GlobeNewswire)
09.10.17	Xbrane Biopharma AB appoints Dina Jurman, Head of Clinical Affairs, to management team (GlobeNewswire)
21.09.17	Xbrane Biopharma AB: Xbrane attends Carnegie Nordic HealthCare Day in New York, 5 December (GlobeNewswire)
11.09.17	Xbrane confirms order of Spherotide to value of SEK 8.5 million and more than 10,000 doses sold (GlobeNewswire)
31.08.17	Xbrane Biopharma releases interim report for the period April - June 2017 (GlobeNewswire)
22.08.17	Information about ongoing discussions and negotiations concerning out-licensing of Xbrane Biopharma AB's (publ) products (GlobeNewswire)
24.07.17	Xbrane Biopharma AB: Spherotide granted Market Authorization in Iran (GlobeNewswire)
21.11.16	Xbrane Biopharma AB (publ) releases interim report for the period July - September 2016 (GlobeNewswire)
01.11.16	Xbrane signs term-sheet for distribution of Spherotide in China generating approx. SEK 70 M in revenue until market approval and expected sales of SEK 350 M annually for Xbrane and the Chinese partner (GlobeNewswire)
31.10.16	Xbrane Biopharma AB ("Xbrane") has received scientific advice regarding regulatory and clinical aspects of the planned submission of a Marketing Authorization Application (MAA) for Spherotide in EU (GlobeNewswire)
31.10.16	Change in number of shares and votes in Xbrane Biopharma (GlobeNewswire)
24.10.16	Xbrane Biopharma AB: Positive outcome of inspection from Italian Medicines Agency - GMP approval of Xbrane's Spherotide production facility is expected in Q1 2017 (GlobeNewswire)
22.08.16	Xbrane Biopharma AB (publ) releases interim report for the period April - June 2016 (GlobeNewswire)
08.08.16	Xbrane Biopharma AB: Oxford Nanopore Technologies licenses Xbrane Biopharma's protein production technology (GlobeNewswire)
01.08.16	Xbrane Biopharma AB: Xbrane submits GMP approval application for the production facility for Spherotide according to time plan (GlobeNewswire)
27.06.16	Xbrane Biopharma AB introduces incentive program (GlobeNewswire)
21.06.16	Xbrane Biopharma completes state of the art laboratory for acceleration of biosimilar development (GlobeNewswire)
07.06.16	Xbrane Biopharma initiates scale-up of production of its Ranibizumab biosimilar Xlucane ahead of plan (GlobeNewswire)
27.05.16	Kommuniké från årsstämma i Xbrane Biopharma AB (publ) (GlobeNewswire)
27.05.16	Xbrane Biopharma AB (publ) publicerar delårsrapport för perioden januari - mars 2016 (GlobeNewswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Kuehne+Nagel Int	204.90	1.19 %	K V
Logitech Intl	74.04	1.18 %	K V
UBS Group	27.01	1.12 %	K V
Roche Hldg G	250.10	1.09 %	K V
Holcim	87.02	1.07 %	K V
Alcon	76.22	0.26 %	K V
Lonza Grp	531.80	0.15 %	K V
Nestle	73.94	-0.05 %	K V
Sonova Hldg	295.40	-0.07 %	K V
Geberit	511.20	-0.58 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Xbrane Biopharma AB

Aktien Top/Flop

Meistgelesene Nachrichten